NanoAb™ | Abnova

VHH antibody, also known as Camelid single domain antibody (sdAb), is the recombinant variable domain derived from camelid heavy-chain-only antibody. This configuration confers some unique properties. The small size and high stability of VHH antibodies make it a promising tool for disease diagnosis and treatment. VHH antibodies can penetrate tissue more easily and target difficult epitopes hidden in the protein structure. Additionally, VHH antibodies express well in many host systems, making it cost-effective for large-scale manufacturing.

Abnova offers the NanoAb™ service for the production of target-specific VHH antibodies from the camelid VHH library. Using advanced camelid VHH library screening technology, we screen the library and isolate the VHH clones for your required antigens. Positive clones are sequenced and validated by ELISA. The selected clones will then be introduced into the mammalian expression vector for scalable VHH antibody production, suitable for many downstream applications. We guarantee the bioactivity of NanoAb™ VHH antibodies expressed in mammalian cells.

Custom_NanoAb.pdf

Workflow

Specification

	Naïve Camelid VHH Library	Immune Library
Library Size	1.2 x 10¹²	1.2 x 10¹³
Required Screening Antigen Amount	0.6 mg	3.5 mg
Lead Time	8-10 weeks	22-24 weeks
Deliverables	Phage validation through phage ELISA data Up to 5 different VHH sequences Up to 1 purified VHH, approximately 0.2 mg per VHH	cDNA 150ug VHH library 3-5ml Phage validation through phage ELISA data Up to 8 different VHH sequences Up to 1 purified VHH, approximately 0.2 mg per VHH

Advantages

Small Size
Superior Stability
Low Immunogenicity
High Affinity and Specificity
Fast Blood Clearance
Versatile Production
Easy Multimerization (Multivalency/Multiparatopicity/Multispecificity)
Easy Conjugation
Robustness in Bioengineering
Applications Across Fields

VHH Antibody vs. Conventional Mab and Pab

	VHH Antibody	Mab	Pab
Size	12 - 15 kD	Approximately 150 kD	Approximately 150 kD
Required Antigen Amount	≦1 mg	≦4 mg	≦4 mg
Method	Camelid VHH library screening	Hybridoma technology	Harvested in antiserum
Stability	High stability to heat, pH, and denaturing agents	Thermal instability	Biological instability
Lot-to-Lot Consistency	Very high	High	Low
Lead Time	8-24 weeks	16-24 weeks	4-12 weeks